Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis, New England Journal of Medicine. 16 févr, vol.376, issue.7, pp.652-62, 2017. ,
Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. Annals of the Rheumatic Diseases, vol.76, pp.88-95, 2017. ,
Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment, Arthritis Rheumatol. mars, vol.69, issue.3, pp.506-523, 2017. ,
Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials, Ann Rheum Dis. juill, vol.76, issue.7, pp.1253-62, 2017. ,
Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment, The Journal of Rheumatology. janv, vol.46, issue.1, pp.7-18, 2019. ,
Rheumatoid arthritis. The Lancet, vol.388, pp.2023-2061, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01890959
American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis: ACR RA TREATMENT RECOMMENDATIONS, Arthritis & Rheumatology. janv, vol.68, issue.1, pp.1-26, 2015. ,
2016 update of the EULAR recommendations for the management of early arthritis, Annals of the Rheumatic Diseases. juin, vol.76, issue.6, pp.948-59, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01794370
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update, Annals of the Rheumatic Diseases. 1 mars, vol.73, issue.3, pp.492-509, 2014. ,
Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases: Miniperspective, Journal of Medicinal Chemistry. 26 juin, vol.57, issue.12, pp.5023-5061, 2014. ,
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Annals of the Rheumatic Diseases, vol.76, pp.960-77, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01778213
CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. The Lancet, févr, vol.381, issue.9865, pp.451-60, 2013. ,
Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis, New England Journal of Medicine. 9 août, vol.367, issue.6, pp.495-507, 2012. ,
Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: A Randomized Trial, Ann Intern Med. 20 août, vol.159, issue.4, p.253, 2013. ,
Tofacitinib versus Methotrexate in Rheumatoid Arthritis, New England Journal of Medicine. 19 juin, vol.370, issue.25, pp.2377-86, 2014. ,
CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve-month data from a twenty-four-month phase III randomized radiographic study, Arthritis & Rheumatism. mars, vol.65, issue.3, pp.559-70, 2013. ,
Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis, New England Journal of Medicine. 9 août, vol.367, issue.6, pp.508-527, 2012. ,
Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis, New England Journal of Medicine. 16 févr, vol.376, issue.7, pp.652-62, 2017. ,
Baricitinib in Patients with Refractory Rheumatoid Arthritis, New England Journal of Medicine. 31 mars, vol.374, issue.13, pp.1243-52, 2016. ,
Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. Annals of the Rheumatic Diseases, vol.76, pp.88-95, 2017. ,
Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment, Arthritis Rheumatol. mars, vol.69, issue.3, pp.506-523, 2017. ,
Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study, Arthritis Res Ther, 2019. ,
Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, Japanese patients with rheumatoid arthritis: an open-label, long-term extension study. Arthritis Research & Therapy [Internet]. déc 2016, vol.18 ,
Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials, Ann Rheum Dis. juill, vol.76, issue.7, pp.1253-62, 2017. ,
Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment, The Journal of Rheumatology. janv, vol.46, issue.1, pp.7-18, 2019. ,
Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis, Rheumatology. 1 févr, vol.58, issue.Supplement_1, pp.34-42, 2019. ,
Herpes Zoster and Tofacitinib Therapy in Patients With Rheumatoid Arthritis. Arthritis Rheumatol, vol.66, pp.2675-84, 2014. ,
Tuberculosis, hepatitis B and herpes zoster in tofacitinibtreated patients with rheumatoid arthritis, Immunotherapy. mars, vol.11, issue.4, pp.321-354, 2019. ,
Cardiovascular Safety During Treatment with Baricitinib in Rheumatoid Arthritis, Arthritis & Rheumatology, 2019. ,
Baricitinib induces LDL-C and HDL-C increases in rheumatoid arthritis: a meta-analysis of randomized controlled trials. Lipids in Health and Disease, Disponible sur, vol.18 ,
Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative, Arthritis Rheum. sept, vol.62, issue.9, pp.2569-81, 2010. ,
URL : https://hal.archives-ouvertes.fr/hal-01557559
Real-World Comparative Risks of Herpes Virus Infections in Tofacitinib and Biologic-Treated Rheumatoid Arthritis Patients, Ann Rheum Dis, vol.75, issue.10, pp.1843-1850, 2016. ,
Efficacy and safety of tofacitinib for the treatment of rheumatoid arthritis in patients from the Asia-Pacific region: Post-hoc analyses of pooled clinical study data, Int J Rheum Dis. juin, vol.22, issue.6, pp.1094-106, 2019. ,
Increased risk of tuberculosis in patients with rheumatoid arthritis, The Journal of Rheumatology. 1 juill, vol.30, issue.7, pp.1436-1445, 2003. ,
Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies, Rheumatology. oct, vol.53, issue.10, pp.1872-85, 2014. ,
Are patients with rheumatoid arthritis still at an increased risk of tuberculosis and what is the role of biological treatments?, Annals of the Rheumatic Diseases. 1 juin, vol.74, issue.6, pp.1212-1219, 2015. ,
Incidence of tuberculosis in patients with rheumatoid arthritis. A systematic literature review, Joint Bone Spine. mai, vol.78, issue.3, pp.279-84, 2011. ,
Rheumatoid arthritis increases the risk of deep vein thrombosis and pulmonary thromboembolism: a nationwide cohort study, Annals of the Rheumatic Diseases, vol.73, issue.10, pp.1774-80, 2014. ,
Comparative Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients Receiving Tofacitinib Versus Those Receiving Tumor Necrosis Factor Inhibitors: An Observational Cohort Study, Arthritis & Rheumatology, vol.71, issue.6, pp.892-900, 2019. ,
Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis ,